Skip to main content

Susan Gail Kreissman, MD

Professor of Pediatrics
Member of the Duke Cancer Institute
Campus mail: 393 Hanes House, Durham, NC 27710
Phone: (919) 684-3401
Email address: kreis001@mc.duke.edu

The emphasis of Dr Kreissman's clinical research involves the study of childhood neuroblastoma. Neuroblastoma is the most common extracranial solid tumor of childhood and this disease has a diverse clinical phenotype and prognosis. Dr Kreissman has developed, written, and served as national protocol chairman for 2 clinical trials designed to improve outcome for children with the high risk form of this disease through the Children's Oncology Group (COG). Results of this protocol have been published " A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma" and established the new standard of using unpurged PBSC to support autologous transplant in high risk neuroblastoma. Dr. Kreissman also serves as a member of the Neuroblastoma committees for COG and is PI for COG studies at Duke. She is involved in designing and implimenting additional new protocols for the treatment of neuroblastoma.

Education and Training

  • Research Fellow, Pediatric Hematology/Oncology, Pediatrics, Children's Hospital, Boston, 1989 - 1991
  • Clinical Fellow, Pediatric Hematology/Oncology, Pediatrics, Children's Hospital, Boston, 1988 - 1989
  • Resident, Pediatrics, Children's Hospital, Boston, 1986 - 1988
  • Intern, Pediatrics, Children's Hospital, Boston, 1985 - 1986
  • M.D., Icahn School of Medicine at Mount Sinai, 1985

Publications

Park, Julie R., Susan G. Kreissman, Wendy B. London, Arlene Naranjo, Susan Lerner Cohn, Michael D. Hogarty, Sheena C. Tenney, et al. “Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial..” Jama 322, no. 8 (August 27, 2019): 746–55. https://doi.org/10.1001/jama.2019.11642.

Full Text

Braunstein, Steve E., Wendy B. London, Susan G. Kreissman, Judith G. Villablanca, Andrew M. Davidoff, Kenneth DeSantes, Robert P. Castleberry, et al. “Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study..” Pediatr Blood Cancer 66, no. 7 (July 2019). https://doi.org/10.1002/pbc.27736.

Full Text

Fangusaro, Jason, Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H. Ligon, Neal Lindeman, Anuradha Banerjee, et al. “Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial..” Lancet Oncol 20, no. 7 (July 2019): 1011–22. https://doi.org/10.1016/S1470-2045(19)30277-3.

Full Text

Pinto, Navin, Arlene Naranjo, Emily Hibbitts, Susan G. Kreissman, M Meaghan Granger, Meredith S. Irwin, Rochelle Bagatell, et al. “Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)..” Eur J Cancer 112 (May 2019): 66–79. https://doi.org/10.1016/j.ejca.2019.02.003.

Full Text

Ezekian, Brian, Michael S. Mulvihill, Paul M. Schroder, Brian F. Gilmore, Harold J. Leraas, Brian C. Gulack, Sarah Jane Commander, et al. “Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma..” Pediatric Transplantation 22, no. 8 (December 2018). https://doi.org/10.1111/petr.13305.

Full Text

Depuydt, Pauline, Valentina Boeva, Toby D. Hocking, Robrecht Cannoodt, Inge M. Ambros, Peter F. Ambros, Shahab Asgharzadeh, et al. “Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients..” J Natl Cancer Inst 110, no. 10 (October 1, 2018): 1084–93. https://doi.org/10.1093/jnci/djy022.

Full Text

Pinto, Navin R., Emily Hibbitts, Susan G. Kreissman, Meaghan P. Granger, Meredith Irwin, Rochelle Bagatell, Wendy B. London, et al. “Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)..” In Journal of Clinical Oncology, 36:10532–10532. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.10532.

Full Text

Yanik, Gregory A., Marguerite T. Parisi, Arlene Naranjo, Helen Nadel, Michael J. Gelfand, Julie R. Park, Ruth L. Ladenstein, et al. “Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1..” J Nucl Med 59, no. 3 (March 2018): 502–8. https://doi.org/10.2967/jnumed.117.195883.

Full Text

Ladenstein, Ruth, Bieke Lambert, Ulrike Pötschger, Maria-Rita Castellani, Valerie Lewington, Zvi Bar-Sever, Aurore Oudoux, et al. “Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials..” Eur J Nucl Med Mol Imaging 45, no. 2 (February 2018): 292–305. https://doi.org/10.1007/s00259-017-3829-7.

Full Text

DuBois, Steven G., Rajen Mody, Arlene Naranjo, Collin Van Ryn, Douglas Russ, Derek Oldridge, Susan Kreissman, et al. “MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group..” Pediatr Blood Cancer 64, no. 11 (November 2017). https://doi.org/10.1002/pbc.26545.

Full Text

Pages